Every 424B that KRAIG BIOCRAFT LABS INC (KBLB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KBLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KBLB filings page.
Registration of 207,787,193 shares of Class A common stock is added via a Prospectus Supplement dated May 22, 2026. The supplement updates the April 30, 2026 prospectus and must be read together with that prospectus.
The company’s Form 10-Q included with the supplement shows 1,113,049,449 shares outstanding as of May 14, 2026, cash and cash equivalents of $2,890,990, and a net loss of $(942,720) for the three months ended March 31, 2026. The filing discloses a going concern qualification due to working capital and stockholders’ deficiencies and notes efforts to raise additional capital.
Kraig Biocraft Laboratories, Inc. files a Prospectus Supplement dated May 22, 2026 registering 306,124,163 shares of Class A common stock. The supplement updates the Prospectus dated May 14, 2026 and incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Form 10-Q shows $2,890,990 in cash as of March 31, 2026, a net loss of $942,720 for the three months ended March 31, 2026, and 1,113,049,449 shares outstanding as of May 14, 2026. Management discloses a working capital deficiency of $7,666,616 and states substantial doubt about going concern.
Kraig Biocraft Laboratories, Inc. registers 306,124,163 shares of Class A Common Stock pursuant to a Prospectus Supplement dated May 22, 2026.
The Prospectus Supplement supplements the Prospectus dated May 14, 2026. As context, shares outstanding were 1,113,049,449 Class A shares as of May 14, 2026. The Company reported a net loss of $(942,720) for the three months ended March 31, 2026 and a working capital deficiency of $(7,666,616), and the financials include a going concern note.
Kraig Biocraft Laboratories has registered 306,124,163 shares of Class A common stock for resale by selling shareholders. The registration covers shares underlying secured convertible notes and warrants from Yorkville transactions, and the Company will not receive proceeds from resale; it will receive cash only if warrants are exercised.
The prospectus states 1,113,049,449 shares outstanding as of May 14, 2026 and discloses a Standby Equity Purchase Agreement providing the Company the right to sell up to $10,000,000 of common stock to an investor subject to conditions and a 4.99% beneficial ownership limit on any single investor.
Kraig Biocraft Laboratories, Inc. is registering 306,124,163 shares of Class A common stock for resale by selling shareholders, consisting primarily of shares underlying Yorkville convertible notes and warrants. The company is not selling any shares here and will receive no proceeds from resales; it will only receive cash if warrants are exercised.
The prospectus states shares outstanding were 1,113,049,449 as of May 14, 2026 and the OTCQB last sale price was $0.1442 per share (May 8, 2026). The registration covers resale methods under the plan of distribution and terminates when the registered shares are sold or may be sold under Rule 144.
Kraig Biocraft Laboratories, Inc. registers for resale up to 207,787,193 shares of Common Stock by YA II PN, Ltd. under a standby equity purchase agreement (SEPA) that permits the company to sell up to $10,000,000 of Common Stock to the investor over a 36-month term. The filing states 1,081,471 Commitment Shares were issued and that 51,443,697 shares have been sold under the SEPA for aggregate gross proceeds of $4,524,430. The company will bear registration expenses; the Selling Stockholder will bear selling commissions. The prospectus notes potential dilution, trading overhang, a going concern qualification in the 2025 and 2024 auditor reports, and that there are 1,106,033,465 shares issued and outstanding as of April 30, 2026.